sutures newsletter

PRODUCED BY AND FOR MEMBERS OF THE DEPARTMENT OF SURGERY May 2016 | Archived Issues

Mark Your Calendar


Surgery Grand Rounds

Click the "read more" to see information about upcoming Surgery Grand Rounds.


Grand Rounds

Click here to view a schedule of all upcoming grand rounds.


Education Schedule

Click the PDF link below to see the Department of Surgery's education schedule.

Education Schedule - May 2016 (PDF)  


Surgery Scheduling

Click the "read more" for hours and contact information for surgery scheduling.

Share Your News

Know an interesting colleague we should profile? A story we should tell? Submit your ideas, meetings and events for consideration.

Click here to submit your news to Sutures

P & T Approvals; Changes in Warnings, Labels for Aripiprazole, Metformin, Fluconazole, Brintellix

Pharmacy Focus

Highlights of the April meeting of the Pharmacy and Therapeutics Committee are summarized in the PDF link below. Also, the U.S. Food and Drug Administration issued a warning regarding reports of impulse-control issues with the use of aripiprazole, has revised the labeling for metformin and is evaluating a study that shows there is a possible increased risk of miscarriage with the use of oral fluconazole. And the agency has approved the name change of the antidepressant Brintellix to Trintellix.

P and T Approvals - April 2016 (PDF)  

FDA: Impulse-Control Problems Possible With Aripiprazole

The FDA issued a warning regarding reports of impulse-control issues (urges to binge eat, shop, gamble and have sex) with the use of the antipsychotic aripiprazole. These uncontrollable urges were reported to have stopped when the medicine was discontinued or the dose was reduced.

The FDA is recommending that healthcare providers alert patients and caregivers of these potential effects. Prescribers should consider reducing the dose or stopping the medication if patients develop these compulsive behaviors.

The FDA website has more information.

FDA Revises Metformin Warnings for Patients With Reduced Kidney Function

The FDA has revised the labeling for metformin regarding patients with impaired renal function.

The FDA concluded, from its review of studies published in the medical literature, that metformin can be used safely in patients with mild impairment in kidney function and in some patients with moderate impairment in kidney function. FDA is requiring changes to the metformin labeling to reflect this new information and provide specific recommendations on the drug's use in patients with mild to moderate kidney impairment.

The FDA website has more information.

FDA Evaluating Use of Oral Fluconazole in Pregnancy

The FDA is evaluating a study that shows there is a possible increased risk of miscarriage with the use of oral fluconazole (Diflucan) for yeast infections.

Until FDA's review is complete and more is understood about this study and other available data, FDA advises cautious prescribing of oral fluconazole in pregnancy.

The FDA website has more information.

Brintellix Changes Name to Trintellix to Avoid Confusion With Brilinta

The FDA has approved the name change of the antidepressant Brintellix to Trintellix to avoid confusion with Brilinta (ticagrelor). Prescribers are advised to include generic names to avoid confusion in the interim. Trintellix tablets will look the same as the previously named Brintellix tablets but will have a new NDC number.

The FDA website has more information.